Predicting cancer-control outcomes in patients with renal cell carcinoma

Current Opinion in Urology

Volumn 19, Issue 3, 2009, Pages 247-257

  Isbarn, Hendrik ^a   Karakiewicz, Pierre I ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Nephrectomy; Nomogram; Predictive tools; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 2; SUNITINIB;

CANCER CONTROL; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; LIFE EXPECTANCY; METASTASIS; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; REVIEW; TREATMENT OUTCOME; KAPLAN MEIER METHOD; KIDNEY TUMOR; NOMOGRAM; PATHOLOGY; PREDICTION AND FORECASTING;

CARCINOMA, RENAL CELL; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; NEPHRECTOMY; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 67649742301     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32832a0814     Document Type: Review

References (43)

1. Karakiewicz PI, Briganti A, Chun FK, et al. Multiinstitutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007; 25:1316-1322. The authors demonstrate that the prediction of RCC-specific survival can be improved if traditional predictor variables are used within a prognostic nomogram.
2. Bhojani N, Salomon L, Capitanio U, et al. External validation of the updated Partin tables in a cohort of French and Italian men. Int J Radiat Oncol Biol Phys 2009; 73:347-352.
3. Karakiewicz PI, Bhojani N, Capitanio U, et al. External validation of the updated Partin tables in a cohort of North American men. J Urol 2008; 180:898-902; discussion 902-1893
4. Bhojani N, Ahyai S, Graefen M, et al. Partin tables cannot accurately predict the pathological stage at radical prostatectomy. Eur J Surg Oncol 2009; 35:123-128.
5. Yaycioglu O, Roberts WW, Chan T, et al. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology 2001;58:141-145.
6. Cindolo L, de la Taille A, Messina G, et al. A preoperative clinical prognostic model for nonmetastatic renal cell carcinoma. BJU Int 2003; 92:901-905.
7. Raj GV, Bach AM, Iasonos A, et al. Predicting the histology of renal masses using preoperative Doppler ultrasonography. J Urol 2007; 177:53-58.
8. Lane BR, Babineau D, Kattan MW, et al. A preoperative prognostic nomogram for solid enhancing renal tumors 7cm or less amenable to partial nephrectomy. J Urol 2007; 178:429-434.
9. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer 2007; 109:1763-1768.
10. Hutterer GC, Patard JJ, Perrotte P, et al. Patients with renal cell carcinoma nodal metastases can be accurately identified: external validation of a new nomogram. Int J Cancer 2007; 121:2556-2561.
11. Raj GV, Thompson RH, Leibovich BC, et al. Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol 2008; 179:2146-2151; discussion 2151.
12. Karakiewicz PI, Suardi N, Capitanio U, et al. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol 2008. [Epub ahead of print]
13. Hutterer GC, Patard JJ, Jeldres C, et al. Patients with distant metastases from renal cell carcinoma can be accurately identified: external validation of a new nomogram. BJU Int 2008; 101:39-43.
14. DeRoche T, Walker E, Magi-Galluzzi C, Zhou M. Pathologic characteristics of solitary small renal masses: can they be predicted by preoperative clinical parameters? Am J Clin Pathol 2008; 130:560-564.
15. Neuzillet Y, Lechevallier E, Andre M, et al. Accuracy and clinical role of fine needle percutaneous biopsy with computerized tomography guidance of small (less than 4.0 cm) renal masses. J Urol 2004; 171:1802-1805.
16. Dimarco DS, Lohse CM, Zincke H, et al. Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy. Urology 2004; 64:462-467.
17. Richstone L, Scherr DS, Reuter VR, et al. Multifocal renal cortical tumors: frequency, associated clinicopathological features and impact on survival. J Urol 2004; 171:615-620.
18. Cindolo L, Patard JJ, Chiodini P, et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 2005; 104:1362-1371.
19. Kattan MW, Reuter V, Motzer RJ, et al. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001; 166:63-67.
20. Frank I, Blute ML, Cheville JC, et al. A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol 2003; 170:2225-2232.
21. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005; 173:48-51.
22. Lam JS, Shvarts O, Leppert JT, et al. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. J Urol 2005; 174:466-472; discussion 472; quiz 801.
23. Hupertan V, Roupret M, Poisson JF, et al. Low predictive accuracy of the Kattan postoperative nomogram for renal cell carcinoma recurrence in a population of French patients. Cancer 2006; 107:2604-2608.
24. Kattan MW. Validating a prognostic model. Cancer 2006; 107:2523-2524.
25. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001; 19:1649-1657.
26. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20:4559-4566.
27. Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002; 168:2395-2400.
28. Thompson RH, Leibovich BC, Lohse CM, et al. Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score. J Urol 2007; 177:477-480.
29. Han KR, Bleumer I, Pantuck AJ, et al. Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. J Urol 2003; 170:2221-2224.
30. Fujii Y, Saito K, Iimura Y, et al. External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma. J Urol 2008; 180:1290-1295; discussion 1295-1296.
31. Zigeuner R, Hutterer G, Chromecki T, et al. External validation of the Mayo Clinic Stage, Size, Grade, and Necrosis (SSIGN) Score for clear-cell renal cell carcinoma in a single European Centre applying routine pathology. Eur Urol 2008. [Epub ahead of print]
32. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988; 48:7310-7313.
33. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17:2530-2540.
34. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289-296.
35. Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. Clin Cancer Res 2004; 10:6302S-6303S.
36. Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003; 98:2566-2575.
37. Leibovich BC, Cheville JC, Lohse CM, et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 2005; 174:1759-1763; discussion 1763.
38. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23:832-841.
39. Escudier B, Choueiri TK, Oudard S, et al. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm froma large phase III trial with shark cartilage extract AE 941. J Urol 2007; 178:1901-1905.
40. Motzer RJ, Bukowski RM, Figlin RA, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008; 113:1552-1558.
41. Karakiewicz PI, Trinh QD, Lam JS, et al. Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality. Eur Urol 2007; 52:1428-1436.
42. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003; 95:634-635.
43. Karakiewicz PI, Trinh QD, de la Taille A, et al. ECOG performance status 0 or 1 and symptom classification do not improve the ability to predict renal cell carcinoma-specific survival. Eur J Cancer 2007; 43:1023-1029.